Posted on October 25, 2018 by Sitemaster
We have just been appraised of a randomized, double-blind, multi-center, Phase III clinical trial of the targeted, radiolabeled agent 177Lu-PSMA-617 (a form of “radioligand” therapy) in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, Lu-177, lutetium-177, metastatic, Phase III, PSMA, trial | 15 Comments »
Posted on January 31, 2018 by Sitemaster
Some readers may have noticed that, late last week, the US Food and Drug Administration (FDA) approved a product known as lutetium Lu-177 dotatate or Lutathera for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: Lu-177, lutetium-177 | 1 Comment »
Posted on September 6, 2017 by Sitemaster
Targeted nuclear medicine has shown some impressive outcomes in several small studies, mostly conducted in Germany. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: Lu-177, lutetium-177, PSMA | 5 Comments »
Posted on March 29, 2017 by Sitemaster
We have been provided (by the developers) with additional information about a US-based, Phase II, clinical trial of a form of radiation therapy using the targeted agent lutetium-177 prostate-specific membrane antigen 617 (177Lu-PSMA-617) for treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: efficacy, Lu-177, mCRPC, PSMA, safety, Treatment, trial | 2 Comments »
Posted on October 27, 2016 by Sitemaster
Because there is great interest in systemic therapies for metastatic prostate cancer, we want to provide readers with the latest news about the 177Lu PSMA-617 trials in Germany. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: Lu-177, metastatic, outcome, PSMA | 3 Comments »
Posted on April 26, 2016 by Sitemaster
One of the more important emerging forms of radiotherapy for metastatic castrate-resistant prostate cancer (mCRPC) is the radioactive element lutetium-177 (177Lu) chemically bonded to a ligand — an antibody or a small molecule that attaches to the prostate-specific membrane antigen (PSMA). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: Lu-177, lutetium, radiation | 10 Comments »
Posted on February 22, 2016 by Sitemaster
There has been a good deal of optimism about the potential efficacy and safety of the radioisotope-labeled product known as prostate-specific membrane antigen-linked lutetium-177 (177Lu-PSMA) in the treatment of very late stage prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, Lu-177, lutetium-177, mCRPC, metastatic, PSMA, Treatment | 4 Comments »
Posted on March 24, 2015 by Sitemaster
Xofigo® (radium Ra-223 dichoride) has been a game-changer in the treatment of prostate cancer metastatic to bone. Not only does it provide significant pain palliation and reduce skeletal-related adverse events, but it slows down progression of the disease, increasing median survival by about 30 percent. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antigen, J591, Lu-177, lutetium, membrane, PSMA, radiation, surface, systemic | 19 Comments »